Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Sebastian P. Haen, MD, Manfred Zierhut, MD, Nora Mirza, PhD, Christoph M. Simon, MD, Andreas Korn, MD, Christoph Faul, MD, Wichard Vogel, MD, Hans-Georg Rammensee, PhD, Lothar Kanz, MD, Wolfgang Bethge, MD

Blood (2016) 128 (22): 4620.

https://doi.org/10.1182/blood.V128.22.4620.4620

Published: 2016

Journal Articles

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Kerstin Maria Kampa-Schittenhelm, MD, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, MD, Lothar Kanz, Prof. Dr. MD, Thomas Haverkamp, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2437.

https://doi.org/10.1182/blood.V126.23.2437.2437

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Impact of Age and Conditioning

Jörg Schmohl, MD, Spanier Lena, Christiane Dorn, MD, Christoph Faul, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang Bethge, MD

Blood (2014) 124 (21): 5939.

https://doi.org/10.1182/blood.V124.21.5939.5939

Published: 2014

Journal Articles

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Sebastian P. Haen, MD, Michael Schumm, DVM, Wichard Vogel, MD, Christoph Faul, MD, Rupert Handgretinger, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2013) 122 (21): 5475.

https://doi.org/10.1182/blood.V122.21.5475.5475

Published: 2013

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 4538.

https://doi.org/10.1182/blood.V122.21.4538.4538

Published: 2013

Journal Articles

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Christoph Simon, Nora Mirza, Wolfgang A. Bethge, MD, Wichard Vogel, MD, Christoph Faul, MD, Hans-Georg Rammensee, Lothar Kanz, MD, Sebastian P. Haen, MD

Blood (2013) 122 (21): 2069.

https://doi.org/10.1182/blood.V122.21.2069.2069

Published: 2013

Journal Articles

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 2084.

https://doi.org/10.1182/blood.V122.21.2084.2084

Published: 2013

Journal Articles

CD34 Selected Stem Cells Boosts Are Safe and Effective for Patients with Poor Bone Marrow Function After Allogeneic Hematopoietic Cell Transplantation.

Sebastian P. Haen, Michael Schumm, DVM, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD, Wichard Vogel, MD

Blood (2012) 120 (21): 3078.

https://doi.org/10.1182/blood.V120.21.3078.3078

Published: 2012

Journal Articles

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Sebastian P. Haen, Benjamin J Schmiedel, PhD, Nora Roth, Christoph Faul, MD, Robert Möhle, Marc Schmalzing, MD, Lothar Kanz, MD, Wichard Vogel, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 1421.

https://doi.org/10.1182/blood.V120.21.1421.1421

Published: 2012

Journal Articles

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Dominik Schneidawind, MD, Sebastian Jendryssek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 4482.

https://doi.org/10.1182/blood.V120.21.4482.4482

Published: 2012

Journal Articles

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

Dominik Schneidawind, MD, Birgit Federmann, MD, Andrea Helwig, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 2041.

https://doi.org/10.1182/blood.V120.21.2041.2041

Published: 2012

Journal Articles

Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.

Nora Roth, Christoph Faul, MD, Christiane Dorn, Wichard Vogel, MD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Hans-Georg Rammensee, Prof., Sebastian P. Haen

Blood (2012) 120 (21): 3060.

https://doi.org/10.1182/blood.V120.21.3060.3060

Published: 2012

Journal Articles

Results of Second or Third Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Patients Failing Primary Transplantation

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2011) 118 (21): 4516.

https://doi.org/10.1182/blood.V118.21.4516.4516

Published: 2011

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Dominik Schneidawind, MD, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2011) 118 (21): 1938.

https://doi.org/10.1182/blood.V118.21.1938.1938

Published: 2011

Journal Articles

Impact of Donor Source and Match on Outcome of Allogeneic Hematopoietic Cell Transplantation with Reduced Intensity Conditioning

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2010) 116 (21): 3539.

https://doi.org/10.1182/blood.V116.21.3539.3539

Published: 2010

Journal Articles

Outcome of Patients Aged ≥60 After Allogeneic Hematopoietec Cell Transplantation: Age Has No Impact on Survival

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2010) 116 (21): 3540.

https://doi.org/10.1182/blood.V116.21.3540.3540

Published: 2010

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation.

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang Andreas Bethge, MD

Blood (2009) 114 (22): 1199.

https://doi.org/10.1182/blood.V114.22.1199.1199

Published: 2009

Journal Articles

Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.

Birgit Federmann, MD, Martin Bornhauser, MD, Lambros Kordelas, MD, Dietrich W. Beelen, MD, Gernot Stuhler, MD, Rainer Schwerdtfeger, MD, Matthias Stelljes, MD, Gerhard Behre, MD, Maximilian Christopeit, MD, Christoph Faul, MD, Wichard Vogel, MD, Rupert Handgretinger, MD, Lothar Kanz, MD, Wolfgang Andreas Bethge, MD

Blood (2009) 114 (22): 1203.

https://doi.org/10.1182/blood.V114.22.1203.1203

Published: 2009

Journal Articles

Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study

Wolfgang A Bethge, MD, Stephanie von Harsdorf, MD, Martin Bornhauser, MD, Dietrich Beelen, MD, Matthias Stelljes, MD, Rainer Schwerdtfeger, MD, Lutz Uharek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Helmut Dittmann, MD, Lothar Kanz, MD, Donald Bunjes, MD

Blood (2008) 112 (11): 2995.

https://doi.org/10.1182/blood.V112.11.2995.2995

Published: 2008

Journal Articles

Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts

Birgit Federmann, MD, Matthias Haegele, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2008) 112 (11): 1175.

https://doi.org/10.1182/blood.V112.11.1175.1175

Published: 2008

NARROW

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Impact of Age and Conditioning

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

CD34 Selected Stem Cells Boosts Are Safe and Effective for Patients with Poor Bone Marrow Function After Allogeneic Hematopoietic Cell Transplantation.

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.

Results of Second or Third Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Patients Failing Primary Transplantation

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Impact of Donor Source and Match on Outcome of Allogeneic Hematopoietic Cell Transplantation with Reduced Intensity Conditioning

Outcome of Patients Aged ≥60 After Allogeneic Hematopoietec Cell Transplantation: Age Has No Impact on Survival

Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation.

Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.

Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study

Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only